



## Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing

September 24, 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Sep. 24, 2024-- [Quantum-Si Incorporated](#) (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced an upcoming webinar that will explore the integration of top-down mass spectrometry (TD-MS) with Quantum-Si's groundbreaking Platinum® instrument. The event, titled "Integrating Top-Down Mass Spectrometry and Single-Molecule Sequencing for Proteoform Analysis," will take place on September 30, 2024.

This webinar will feature Dr. Michael Caldwell, Scientific Officer at Northwestern University's Proteomics Center of Excellence, and Dr. Meredith Carpenter, Head of Scientific Affairs at Quantum-Si. Dr. Caldwell will provide insights into the latest advancements in proteoform analysis, illustrating how the combination of TD-MS and Quantum-Si's Platinum offers unmatched precision in detecting and characterizing proteins at the single-molecule level.

"At Quantum-Si, we are committed to pushing the boundaries of proteomics by introducing cutting-edge technologies that provide researchers precision in protein analysis," said Jeff Hawkins, CEO of Quantum-Si. "This webinar is a unique opportunity for scientists and innovators to explore how the integration of top-down mass spectrometry and our Next-Gen Protein Sequencing™(NGPS) platform can revolutionize proteoform detection, ultimately advancing discoveries in disease research and therapeutic development."

"Proteoforms provide the greatest level of insight into protein biology, and the need for advanced technologies to accurately and comprehensively characterize them is growing," said Dr. Caldwell. "We are very interested in new technologies and driving forward the field of proteoform identification and discovery, and Platinum is a key part of that effort." Employing NGPS for precise proteoform detection and analysis complements traditional approaches, and enables novel discoveries related to the role of proteoforms in health and disease.

### Event Details:

**Date:** September 30, 2024

**Time:** 12:00PM Eastern/9:00AM Pacific

**Hosted by:** Select Science®

**Registration Link:** [Enhance proteoform analysis through the integration of top-down mass spectrometry and single-molecule sequencing \(selectscience.net\)](#)

### About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at [quantum-si.com](#) or follow us on [LinkedIn](#) or [X](#).

### Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum™ protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240924105683/en/): <https://www.businesswire.com/news/home/20240924105683/en/>

**Investor Contact**

Doug Farrell, VP, Investor Relations

[ir@quantum-si.com](mailto:ir@quantum-si.com)

**Media Contact**

Katherine Atkinson, SVP, Commercial Marketing

[media@quantum-si.com](mailto:media@quantum-si.com)

Source: Quantum-Si Incorporated